DPP-4抑制剂西格列汀主要中国证据盘点

Chinese Evidence of DPP-4 Inhibitor Sitagliptin

随着二肽基肽酶-4(dipeptidyl peptidase-4,DPP-4)抑制剂在国内的大规模应用,尤其是进入医保目录之后,DPP-4抑制剂在中国人群中的应用越来越广泛,积累了大量的循证证据,为中国糖尿病管理提供了更多的选择。西格列汀作为首个上市的DPP-4抑制剂,可通过增加活性肠促胰素水平而改善2型糖尿病患者的血糖控制。大量循证据表明,西格列汀不论单药还是联合用药均具有良好的有效性及安全性,低血糖风险低,不增加体重,有潜在的心血管及微血管临床获益,满足2型糖尿病患者的临床需要。

Recently,with the large-scale application of DPP-4 inhibitors in China,especially after entering the medical insurance directory,DPP-4 inhibitors have Chinese population and accumulated a large amount of evidence-based evidence.It provides more choices for diabetes management in China.As the first available DPP-4 inhibitor,been more and more widely used in the siglitatin can improve blood glucose control in type 2 diabetic patients by increasing the level of active intestinal trypsin.There is plenty of evidence to show that siglitatin is effective and safe on both single and combined drugs,has a low risk of hypoglycemia,does not gain weight,and has potential cardiovascular and microvascular clinical benefits.To meet the clinical needs of patients with type 2 diabetes.